Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System
ConclusionsDespite increases over time, overall utilization of nirmatrelvir/ritonavir was low. Predictors of nirmatrelvir/ritonavir utilization were consistent with known risk factors for progression to severe COVID-19, including older age and underlying medical conditions. Unvaccinated and undervaccinated patients and those receiving potentially interacting medications for cardiovascular or mental health conditions (antiarrhythmic, alpha-1 antagonist, anticoagulant/antiplatelet, sedative/hypnotic/psychiatric) were less likely to receive nirmatrelvir/ritonavir. Further education of prescribers and patients about nirmatrelv...
Source: Infectious Diseases and Therapy - January 13, 2024 Category: Infectious Diseases Source Type: research
Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases
ConclusionOur study demonstrates that the treatment of colistin sulfate can achieve high clinical efficacy and microbial responses, with a low risk of nephrotoxicity. This study provides evidence of the positive clinical efficacy and safety of colistin sulfate treatment in these patients. High-quality randomized controlled trials are still needed to further confirm the beneficial role of colistin sulfate. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 11, 2024 Category: Infectious Diseases Source Type: research
Remdesivir for the Treatment of COVID-19: A Narrative Review
AbstractDespite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US Food and Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir is currently the only recommended antiviral for use in hospitalized patients with COVID-19, with or without a supplemental oxygen requirement. It is also recommended for nonhospitalized patients with COVID-19 and hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk of prog...
Source: Infectious Diseases and Therapy - January 9, 2024 Category: Infectious Diseases Source Type: research
Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study
ConclusionHZ and PHN risk in Sweden is comparable to that in other European countries prior to implementing HZ national vaccination programs. Municipal differences suggest that the lifetime risk of HZ in Sweden is at least 36.5%.Clinical Trial RegistrationNCT Number (www.clinicaltrials.gov).Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 9, 2024 Category: Infectious Diseases Source Type: research
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies
ConclusionAER001 and AER002 showed an acceptable safety profile and extended half-life. High serum neutralization activity was observed against D614G and Omicron BA.1 compared to the placebo group. These data support that LS-modified mAbs can achieve durability, safety, potency, and upper airway tissue penetration and will guide the development of the next generation of mAbs for COVID-19 prevention and treatment.Trial RegistrationEudraCT Number 2022-001709-35 (COV-2022-001). (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
ConclusionsThis large-scale survey showed that molnupiravir was safe and effective in real-world settings in highly vaccinated Japanese patients with COVID-19, including older patients and those with comorbidities. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System
ConclusionsDespite increases over time, overall utilization of nirmatrelvir/ritonavir was low. Predictors of nirmatrelvir/ritonavir utilization were consistent with known risk factors for progression to severe COVID-19, including older age and underlying medical conditions. Unvaccinated and undervaccinated patients and those receiving potentially interacting medications for cardiovascular or mental health conditions (antiarrhythmic, alpha-1 antagonist, anticoagulant/antiplatelet, sedative/hypnotic/psychiatric) were less likely to receive nirmatrelvir/ritonavir. Further education of prescribers and patients about nirmatrelv...
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Remdesivir for the Treatment of COVID-19: A Narrative Review
AbstractDespite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US Food and Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir is currently the only recommended antiviral for use in hospitalized patients with COVID-19, with or without a supplemental oxygen requirement. It is also recommended for nonhospitalized patients with COVID-19 and hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk of prog...
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
ConclusionCompared to placebo, RBL demonstrated a significantly higher treatment success in preventing further rCDI and enhanced HRQL among patients at first recurrence, establishing RBL as an effective treatment to prevent further recurrences in these patients.Trial RegistrationClinicalTrials.gov Identifier NCT03244644. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study
ConclusionHZ and PHN risk in Sweden is comparable to that in other European countries prior to implementing HZ national vaccination programs. Municipal differences suggest that the lifetime risk of HZ in Sweden is at least 36.5%.Clinical Trial RegistrationNCT Number (www.clinicaltrials.gov).Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases
ConclusionOur study demonstrates that the treatment of colistin sulfate can achieve high clinical efficacy and microbial responses, with a low risk of nephrotoxicity. This study provides evidence of the positive clinical efficacy and safety of colistin sulfate treatment in these patients. High-quality randomized controlled trials are still needed to further confirm the beneficial role of colistin sulfate. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile
ConclusionsIncidence of LRTI, including that due to RSV, especially for events requiring acute inpatient care, is markedly higher among older adults and adults of all ages with CMC or IC. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 1, 2024 Category: Infectious Diseases Source Type: research
Global Prevalence of Varicella-Associated Complications: A Systematic Review and Meta-Analysis
ConclusionResults suggest that different types of varicella-associated complications could be frequent, impacting quality of life, and healthcare resource utilisation and budgets. These findings are crucial to raise awareness of the health and economic burden of varicella disease. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - December 19, 2023 Category: Infectious Diseases Source Type: research
Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein
ConclusionThe calculation of the probability for bacterial infection using MxA and CRP may efficiently discriminate between viral and bacterial respiratory infections. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - December 19, 2023 Category: Infectious Diseases Source Type: research
Global Prevalence of Varicella-Associated Complications: A Systematic Review and Meta-Analysis
ConclusionResults suggest that different types of varicella-associated complications could be frequent, impacting quality of life, and healthcare resource utilisation and budgets. These findings are crucial to raise awareness of the health and economic burden of varicella disease. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - December 19, 2023 Category: Infectious Diseases Source Type: research
